Comment
doi: 10.1016/s0140-6736(99)03132-3.
Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications
- PMID: 10560679
- DOI: 10.1016/s0140-6736(99)03132-3
Item in Clipboard
Comment
Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications
Lancet.
.
Abstract
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
Comment on
-
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.Lancet. 1995 Dec 16;346(8990):1575-82. Lancet. 1995. PMID: 7500748
-
Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.Lancet. 1996 Aug 24;348(9026):498-505. Lancet. 1996. PMID: 8757151
-
Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.Lancet. 1996 Aug 24;348(9026):505-10. Lancet. 1996. PMID: 8757152
-
Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.Lancet. 1997 Apr 26;349(9060):1202-9. Lancet. 1997. PMID: 9130941
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
